Abstract
Patients who have achieved very low low-density lipoprotein CH (LDL-C) levels in clinical trials have shown the lowest cardio-vascular risk. The current clinical guidelines set such a concentration for LDL-C as < 1.4 mmol/L. However, the question of minimum permissible target values of the lipids remains unresolved. A number of experimental and clinical studies showed some unfavorable consequences of low LDL-C levels At the same time, the modern arsenal of lipid lowering drugs allows reducing LDL-C levels to extremely low values. This review presents an analysis of literature about the safety of low lipid spectrum parameters.
Keywords: Low-density lipoprotein CH (LDL-C), PCSK9 inhibitors, statins, diabetes mellitus, immune system, malignant neoplasms, brain function.
Current Pharmaceutical Design
Title:The State of the Problem of Achieving Extremely Low LDL Levels
Volume: 27 Issue: 37
Author(s): Victoria Korneva*, Tatiana Kuznetsova and Ulrich Julius
Affiliation:
- Petrozavodsk State University, Faculty Therapy Department, 185000 Lenin Ave., 33, Petrozavodsk,Russian Federation
Keywords: Low-density lipoprotein CH (LDL-C), PCSK9 inhibitors, statins, diabetes mellitus, immune system, malignant neoplasms, brain function.
Abstract: Patients who have achieved very low low-density lipoprotein CH (LDL-C) levels in clinical trials have shown the lowest cardio-vascular risk. The current clinical guidelines set such a concentration for LDL-C as < 1.4 mmol/L. However, the question of minimum permissible target values of the lipids remains unresolved. A number of experimental and clinical studies showed some unfavorable consequences of low LDL-C levels At the same time, the modern arsenal of lipid lowering drugs allows reducing LDL-C levels to extremely low values. This review presents an analysis of literature about the safety of low lipid spectrum parameters.
Export Options
About this article
Cite this article as:
Korneva Victoria *, Kuznetsova Tatiana and Julius Ulrich , The State of the Problem of Achieving Extremely Low LDL Levels, Current Pharmaceutical Design 2021; 27 (37) . https://dx.doi.org/10.2174/1381612827999210111182030
DOI https://dx.doi.org/10.2174/1381612827999210111182030 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Noradrenergic Regulation of Glial Activation: Molecular Mechanisms and Therapeutic Implications
Current Neuropharmacology Cardiovascular Complications of Obesity
Current Respiratory Medicine Reviews Role of Transcranial Doppler Ultrasonography in Cerebrovascular Disease
Recent Patents on CNS Drug Discovery (Discontinued) Allocentric to Egocentric Spatial Switching: Impairment in aMCI and Alzheimer's Disease Patients?
Current Alzheimer Research HIV-1 Subtypes B and C Tat Differentially Impact Synaptic Plasticity Expression and Implicates HIV-Associated Neurocognitive Disorders§
Current HIV Research Analytical Tools for the Determination of Antioxidants and Antioxidant Capacity in Biological Samples, Principles and Applications
Current Organic Chemistry Levodopa in Parkinson’s Disease: Current Status and Future Developments
Current Neuropharmacology Nose to Brain Delivery of Nanoformulations for Neurotherapeutics in Parkinson’s Disease: Defining the Preclinical, Clinical and Toxicity Issues
Current Drug Delivery Lafora Progressive Myoclonus Epilepsy: Recent Insights into Cell Degeneration
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Pathological Gambling: Update on Decision Making and Neuro-functional Studies in Clinical Samples
Current Pharmaceutical Design Screening of Enzyme Inhibitors from Traditional Chinese Medicine
Combinatorial Chemistry & High Throughput Screening An Expedient Synthesis and Screening for Antiacetylcholinesterase Activity of Piperidine Embedded Novel Pentacyclic Cage Compounds
Medicinal Chemistry Smoking and Cognition
Current Drug Abuse Reviews Lipophilic Analogs of Thioflavin S as Novel Amyloid-Imaging Agents
Current Alzheimer Research Editorial [Hot topic: Antiretroviral, Anti-Inflammatory and Dopaminergic Substances in the Treatment of HIV-Infection (Guest Editor: Gabriele Arendt)]
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Effect of the Interaction Between Hypertension and Cerebral White Matter Changes on the Progression of Alzheimer Disease
Current Alzheimer Research The Pleiotropic Effects of Statins in Endocrine Disorders
Endocrine, Metabolic & Immune Disorders - Drug Targets Diet-Derived Phytochemicals: From Cancer Chemoprevention to Cardio-Oncological Prevention
Current Drug Targets Polyphenols and Neuroprotection against Ischemia and Neurodegeneration
Mini-Reviews in Medicinal Chemistry Effect of S-equol and Soy Isoflavones on Heart and Brain
Current Cardiology Reviews